144 related articles for article (PubMed ID: 36109467)
1. Development of Novel Solid Nanostructured Lipid Carriers for Bioavailability Enhancement Using a Quality by Design Approach.
Bajwa N; Mahal S; Naryal S; Singh PA; Baldi A
AAPS PharmSciTech; 2022 Sep; 23(7):253. PubMed ID: 36109467
[TBL] [Abstract][Full Text] [Related]
2. Optimized Nanoparticles for Enhanced Oral Bioavailability of a Poorly Soluble Drug: Solid Lipid Nanoparticles Versus Nanostructured Lipid Carriers.
Darwish MKM; El-Enin ASMA; Mohammed KHA
Pharm Nanotechnol; 2022; 10(1):69-87. PubMed ID: 35142275
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks.
Elmowafy M; Ibrahim HM; Ahmed MA; Shalaby K; Salama A; Hefesha H
Drug Deliv; 2017 Nov; 24(1):932-941. PubMed ID: 28617150
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
Dudhipala N; Janga KY; Gorre T
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
[TBL] [Abstract][Full Text] [Related]
5. Physical characterization and bioavailability assessment of 5-fluorouracil-based nanostructured lipid carrier (NLC): In vitro drug release, Hemolysis, and permeability modulation.
Mainuddin ; Kumar A; Ratnesh RK; Singh J; Dumoga S; Sharma N; Jindal A
Med Oncol; 2024 Mar; 41(5):95. PubMed ID: 38526657
[TBL] [Abstract][Full Text] [Related]
6. Formulation, Characterization, and Pharmacokinetic Studies of 6-Gingerol-Loaded Nanostructured Lipid Carriers.
Wei Q; Yang Q; Wang Q; Sun C; Zhu Y; Niu Y; Yu J; Xu X
AAPS PharmSciTech; 2018 Nov; 19(8):3661-3669. PubMed ID: 30324361
[TBL] [Abstract][Full Text] [Related]
7. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus.
Yu Q; Hu X; Ma Y; Xie Y; Lu Y; Qi J; Xiang L; Li F; Wu W
Drug Deliv; 2016 May; 23(4):1469-75. PubMed ID: 27187522
[TBL] [Abstract][Full Text] [Related]
8. Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration.
Akpa PA; Ugwuoke JA; Attama AA; Ugwu CN; Ezeibe EN; Momoh MA; Echezona AC; Kenechukwu FC
Afr Health Sci; 2020 Dec; 20(4):1679-1697. PubMed ID: 34394228
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization, and
Saghafi Z; Mohammadi M; Mahboobian MM; Derakhshandeh K
Drug Dev Ind Pharm; 2021 Mar; 47(3):509-520. PubMed ID: 33650445
[TBL] [Abstract][Full Text] [Related]
10. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study.
Shah NV; Seth AK; Balaraman R; Aundhia CJ; Maheshwari RA; Parmar GR
J Adv Res; 2016 May; 7(3):423-34. PubMed ID: 27222747
[TBL] [Abstract][Full Text] [Related]
11. Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy.
Pyo YC; Tran P; Kim DH; Park JS
Colloids Surf B Biointerfaces; 2020 Dec; 196():111331. PubMed ID: 32906001
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of S(+)-zaltoprofen oral bioavailability using nanostructured lipid carrier system.
Pham TMA; Lee DH; Na YG; Jin M; Jung M; Kim HE; Yoo H; Won JH; Lee JY; Baek JS; Han SC; Lee HK; Cho CW
Arch Pharm Res; 2022 Nov; 45(11):822-835. PubMed ID: 36307644
[TBL] [Abstract][Full Text] [Related]
13. Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies.
Singh A; Neupane YR; Mangla B; Kohli K
J Pharm Sci; 2019 Oct; 108(10):3382-3395. PubMed ID: 31201904
[TBL] [Abstract][Full Text] [Related]
14. Optimization of Nanostructured Lipid Carriers of Fenofibrate Using a Box-Behnken Design for Oral Bioavailability Enhancement.
Wang H; Hong W; Li X; Jin Q; Ye W; Feng Y; Huang B; Tai Z; Chen L; Li Z; Wang Y; Yang Y; Gao C; Gong W; Yang M
Curr Drug Deliv; 2022; 19(7):773-787. PubMed ID: 33902411
[TBL] [Abstract][Full Text] [Related]
15. Preparation of Ergosterol-Loaded Nanostructured Lipid Carriers for Enhancing Oral Bioavailability and Antidiabetic Nephropathy Effects.
Dong Z; Iqbal S; Zhao Z
AAPS PharmSciTech; 2020 Jan; 21(2):64. PubMed ID: 31932990
[TBL] [Abstract][Full Text] [Related]
16. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
[TBL] [Abstract][Full Text] [Related]
17. Strategies to enhance oral delivery of amphotericin B: a comparison of uncoated and enteric-coated nanostructured lipid carriers.
Nimtrakul P; Sermsappasuk P; Tiyaboonchai W
Drug Deliv; 2020 Dec; 27(1):1054-1062. PubMed ID: 32633144
[TBL] [Abstract][Full Text] [Related]
18. Quality by design (QbD)-based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies.
Gurumukhi VC; Bari SB
Drug Deliv Transl Res; 2022 May; 12(5):1230-1252. PubMed ID: 34110597
[TBL] [Abstract][Full Text] [Related]
19. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.
Zhou X; Zhang X; Ye Y; Zhang T; Wang H; Ma Z; Wu B
Int J Pharm; 2015 Feb; 479(2):391-8. PubMed ID: 25556104
[TBL] [Abstract][Full Text] [Related]
20. Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers.
Zhou J; Zhou D
Drug Des Devel Ther; 2015; 9():5269-75. PubMed ID: 26425076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
